A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-18. Anything still debated is marked as such rather than presented as settled.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
On September 28 Hanmi and Zentec Pharmaceuticals agreed that Zentec would market Hanmi's small molecule cancer drug candidate, HM95573; Zentec paid $80 million upfront, with $830 million in milestones, and royalties. On September 29, Hanmi and Roche's cancer subsidiary Genentech announced a deal for Hanmi's Phase I cancer drug candidate, HM95573, which targets the MAPK/ERK pathway; Roche agreed to pay $80 million upfront, and the deal included $830 million in milestones. In December 2016 the Sanofi deal was reduced in scope, with Hanmi receiving back rights to the once-weekly insulin and the combination GLP1-RA/insulin product, and agreeing to repay Sanofi $250 million of the $434 million upfront payment. On December 3, 2019, Rapt Therapeutics and Hanami Pharmaceutical announced collaboration to develop and commercialize FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers. In August 2020, chairman and founder of Hanmi Pharmaceutical Lim Sung-ki died of a chronic disease. He was 80. On May 15, 2023, Athenex, which was Hanmi's U.S. partner for its anticancer product, Oraxol, filed for Chapter 11 bankruptcy protection.
By the 1930s, multiple researchers concluded that tobacco use caused cancer and that tobacco users lived substantially shorter lives. Further studies were published in Germany in 1939 and 1943, and one in the Netherlands in 1948. However, widespread attention was first drawn in 1950 by researchers from the United States and the United Kingdom, but their research was widely criticized. Follow-up studies in the early 1950s found that people who smoked died faster and were more likely to die of lung cancer and cardiovascular disease. These results were accepted in the medical community and publicized among the general public in the mid-1960s.
=== 18 March === President Putin visited Crimea on the ninth anniversary of the peninsula's annexation. The Black Sea Grain Initiative between Ukraine and Russia, which was due to expire on 18 March, was extended.
=== FORTUNE, Modern Healthcare and Press Ganey awards === Southern Ohio Medical Center has been recognized as one of FORTUNE Magazine’s Best Places to Work in America for six straight years. In 2013, it came in 29th on the list with FORTUNE noting: “Employees are proud to work for a medical provider that has won numerous awards for patient care, a fact that's reflected in its average tenure. Nearly 20% of the staff has worked there for more than 20 years.” SOMC was recognized on the FORTUNE list again in 2014 (coming in 18th) and 2015 (coming in 44th). In the 2015 survey, 93% of SOMC employees described their workplace as "a great place to work." Modern Healthcare Magazine also recognized SOMC as one of the nation's best healthcare employers in 2010, 2011 and 2012. In 2012, Southern Ohio Medical Center was one of only 13 Press Ganey clients in the nation to be chosen as a Distinctive Workplace Award winner. The award was given to organizations that reached, and sustained, the 95th percentile in employee satisfaction – SOMC was at the 99th percentile.
William said in 1985, "We all love The Shangri-Las, and one day we're going to make Shangri-Las records." Jim mentioned his liking for Pink Floyd, Siouxsie and the Banshees, The Monkees, and Muddy Waters. Early demos displayed a similarity to the Ramones, prompting the brothers to add another element to their sound; in William's words: "That's why we started using noise and feedback. We want to make records that sound different." They began playing live in early 1984. In the early days William Reid's guitar would be left out of tune, while Dalglish's drum kit was limited to two drums, and Hart's bass guitar only had three strings, down to two by 1985; in Hart's words, "That's the two I use. I mean what's the fucking point spending money on another two? Two is enough." Struggling to get gigs, the band took to turning up at venues claiming to be the support band, playing their short set and making a quick exit. After failing to generate any interest from concert promoters and record labels in Scotland, the band relocated to Fulham, London, in May 1984, and soon afterwards their demo tape was passed to fellow Scot Alan McGee by Bobby Gillespie. Subsequently, McGee promoted a gig for the band at the Living Room in London in June 1984. On the strength of hearing the band sound check, McGee signed them to his Creation Records label on a one-off deal, and McGee also became the band's manager. Their debut single, "Upside Down", was recorded in October and released in November that year.
Sources: en.wikipedia.org
==== White Belizeans ==== Whites in Belize form around 4.8% of the population. A minority of less than one percent is from Ireland, the United Kingdom, the United States, Canada, Lebanon, and other countries brought to assist the country's development. Irish settlers and migrants and veterans from Louisiana and other Southern states established Confederate settlements in British Honduras and introduced commercial sugar cane production to the colony, establishing 11 settlements in the interior. The largest White group of almost four percent are the German speaking Mennonites who form a spectrum from very traditional and conservative groups like the Old Colony Mennonites and the Noah Hoover Mennonites to more modern groups like the Kleine Gemeinde, the Church of God in Christ, Mennonite (Holdeman Mennonites) and groups belonging to the Evangelical Mennonite Mission Conference.
=== Red flags === Imaging is not typically needed in the initial diagnosis or treatment of back pain. However, if there are certain "red flag" symptoms present, plain radiographs (X-ray), CT scan or magnetic resonance imaging may be recommended. These red flags include:
A key advantage of chemiluminescence-based electronic devices is their high reliability and resistance to interference from substances such as perfumes, dirt, and human sweat, as well as their ability to operate effectively under challenging environmental conditions, including variations in temperature and humidity. Therefore they are very capable in the field. These devices does not uses radioactive ionizing source. These features are enabled by IRSSIL technology developed by RS DYNAMICS, powering the compact yet fast and capable miniEXPLONIX Pro detector, as well as the advanced EXPLONIX 2 analyzer.
== Further reading == Rees, Jonathan. Refrigeration Nation: A History of Ice, Appliances, and Enterprise in America (Johns Hopkins University Press; 2013) 256 pages Refrigerators and food preservation in foreign countries. United States Bureau of Statistics, Department of State. 1890.
Sources: en.wikipedia.org
== Controversies by country == Certain border control policies of various countries have been the subject of controversy and public debate. Public opinion on border control and closing borders varies by country.
The full face mask does not usually have a bailout block fitted, and this is usually attached to the diver's harness, with a single hose to supply the mask from main or bailout gas which is selected at the block. The strap arrangement for full face masks is usually quite secure, but not as secure as a bandmask or helmet, and it is possible for it to be dislodged in the water. However it is also quite practicable for a trained diver to replace and clear a full face mask under water without assistance, so this is more an inconvenience than a disaster unless the diver is rendered unconscious at the same time.
== External links == GeneReviews/NIH/NCBI/UW entry on Tyrosine Hydroxylase Deficiency including Tyrosine Hydroxylase-Deficient Dopa-Responsive Dystonia or Segawa Syndrome and Autosomal Recessive Infantile Parkinsonism Tyrosine+hydroxylase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
July 4 July 4 – The U.S. celebrates its semiquincentennial, in recognition of the 250th anniversary of the 1776 adoption of the United States Declaration of Independence from Great Britain. The Department of Government Efficiency officially shuts down operations. July 5 The Navy suspends its search for one of its missing soldiers in the Arabian Sea. 2026 FIFA World Cup: FIFA suspends the automatic one-match ban given to United States forward Folarin Balogun following his red card against Bosnia and Herzegovina, allowing him to play in the round of 16 against Belgium, after President Trump personally urged FIFA president Gianni Infantino to review the case. The decision is criticised by UEFA and the Royal Belgian Football Association. July 6 Iran war: US president Donald Trump says that the US government will either make an agreement with the Iranian regime or "finish the job" against it, claiming that Americans have the capability to destroy their bridges in one hour, and destroy their energy supply. 2026 United States Senate elections: Amidst ongoing controversies surrounding U.S. Senate nominee Graham Platner (D-ME) including a recent sexual assault allegation, Platner says that he will consider "taking the time" to consider his next steps in the race. 2026 FIFA World Cup: Co-hosts United States are eliminated from the tournament after losing 4–1 to Belgium in the round of 16 at Lumen Field in Seattle. July 7 – Amidst ongoing speculation regarding the health of U.S. Senator Mitch McConnell (R-KY), spokespersons for Republican leaders including U.S.
The hepatocyte is a complex and multifunctional differentiated cell whose cell response will be influenced by the zone in hepatic lobule, because concentrations of oxygen and toxic substances present in the hepatic sinusoids change from periportal zone to centrilobular zone10. The hepatocytes of the intermediate zone have the appropriate morphological and functional features since they have the environment with average concentrations of oxygen and other substances. This specialized cell is capable of:
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.